SC 45355
Latest Information Update: 26 Jul 1994
Price :
$50 *
At a glance
- Originator University of Milan
- Class Antihyperlipidaemics
- Mechanism of Action HMG-CoA reductase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Hyperlipidaemia